65 results
8-K
EX-99.1
ATXI
Avenue Therapeutics Inc
18 Mar 24
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
4:10pm
of acute post-operative pain in a medically supervised setting. The final non-inferiority study is designed to assess the theoretical risk of opioid … -induced respiratory depression related to opioid stacking on IV tramadol compared to IV morphine. The study will randomize approximately 300 post
424B3
ATXI
Avenue Therapeutics Inc
2 Feb 24
Prospectus supplement
12:00am
to support the position that the benefits of their product outweigh the risks for the management of acute pain severe enough to require an opioid … with the FDA in March 2023 to discuss a proposed study protocol to assess the risk of respiratory depression related to opioid stacking on IV tramadol
8-K
EX-99.1
0wvj91z0ebo
13 Nov 23
Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
4:10pm
424B4
eoucmrno
2 Nov 23
Prospectus supplement with pricing info
9:00am
FWP
e0a4mqzld9gbrd7f1xp
5 Oct 23
Free writing prospectus
5:05pm
FWP
n94p fb556
3 Oct 23
Free writing prospectus
5:47pm
8-K
EX-99.1
79477o9
10 Aug 23
Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
4:20pm
424B3
7c4yb1hwumu6 kerh0hr
28 Jun 23
Prospectus supplement
4:56pm
8-K
EX-99.1
2j6x y9k7z
12 May 23
Avenue Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
8:35am
424B3
1a0kz4ms7vvgwzv1eb
4 May 23
Prospectus supplement
4:30pm
8-K
EX-99.1
iir3zpb6 iw
17 Apr 23
Avenue Therapeutics Announces Regulatory Update Based on Type C Meeting with FDA and Next Steps in the Development of IV Tramadol
4:06pm